Mental health – Page 3

Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults – A Systematic Review

mycolabadmin

Psilocybin, a naturally occurring compound found in certain mushroom species, shows significant promise as a treatment for depression. Clinical studies reviewed in this research found that psilocybin-assisted therapy reduced depressive symptoms in every patient studied, with improvements lasting months after treatment. Unlike traditional antidepressants, psilocybin caused only mild temporary side effects and worked faster, suggesting it could become an important alternative treatment for depression.

Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study

mycolabadmin

This study examines how antidepressant medications (like SSRIs) affect the experience of classic psychedelics such as psilocybin and LSD. Researchers found that people taking these antidepressants experienced less intense emotional and mystical effects from psychedelics, but surprisingly, both groups showed similar improvements in mood and well-being several weeks later. This raises important questions about whether patients need to stop their antidepressants before using psychedelics therapeutically.

The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects

mycolabadmin

This review examines how psilocybin may help treat depression by increasing empathy and prosocial behavior. While psilocybin leaves the body within hours, its antidepressant effects can last months, and researchers believe empathy and helping others may explain this lasting benefit. The authors suggest psilocybin starts a positive cycle where increased empathy leads to helping others, which boosts mood and well-being, which further reinforces empathetic behavior.

Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey

mycolabadmin

This survey studied how autistic adults feel about using psychedelics like psilocybin mushrooms for mental health. Nearly 70% of participants had tried psychedelics before and most found them helpful for anxiety and depression. Many participants were interested in trying them or participating in research, though legal and practical barriers stood in the way. The study suggests that psychedelics could be a promising treatment option for autistic people with mental health challenges.

The Immune Mind: Linking Dietary Patterns, Microbiota, and Psychological Health

mycolabadmin

This review shows that what we eat significantly affects our mental health through our gut bacteria and immune system. Mediterranean-style diets rich in vegetables, whole grains, and healthy fats can help reduce depression and anxiety symptoms. Conversely, ultra-processed foods with added sugars and artificial ingredients increase the risk of mental health problems. Specific probiotic supplements may also provide modest benefits for mood by promoting beneficial gut bacteria.

We need to talk about shrooms

mycolabadmin

The article discusses how psychedelic mushrooms have transformed from being seen as dangerous drugs in the 1960s to being studied as potential psychiatric treatments today. While research shows promise for treating depression, trauma, and addiction, the author warns against oversimplified narratives that ignore important context about how these experiences work and potential risks. The piece calls for careful, balanced discussion about psychedelics that considers both benefits and concerns.

A clinical protocol for group-based ketamine-assisted therapy in a community of practice: the Roots To Thrive model

mycolabadmin

The Roots to Thrive ketamine-assisted therapy program is a 12-week group treatment that combines ketamine sessions with weekly group meetings, somatic practices, and emotional support. The program integrates both Western clinical approaches and Indigenous wisdom, treating depression, anxiety, and PTSD in groups of 20-40 participants. Over 750 people have participated with significant improvements in mental health symptoms and life functioning, demonstrating that this group-based approach is both safe and effective.

Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology

mycolabadmin

Psilocybin, the active compound in magic mushrooms, shows promise for treating depression and other mental health conditions. This review examines how psilocybin works in the brain, particularly by affecting brain regions involved in self-reflection and emotion regulation. The authors argue that new brain recording techniques are needed to fully understand how psilocybin produces its beneficial effects, which could help improve treatments for people with severe depression.

Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial

mycolabadmin

This study tests whether psilocybin (a psychedelic compound) combined with intensive therapy can help treat chronic PTSD better than therapy alone. Fifteen patients with PTSD will receive one dose of psilocybin alongside 12 therapy sessions completed over a single week. Researchers will track feasibility, safety, symptom improvements, and use wearable devices to monitor physiological changes. The results will help determine whether larger trials should test this innovative combination therapy.

The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience, or setting

mycolabadmin

A research study examined how psilocybin experiences affect long-term mental health and well-being in healthy volunteers. Participants received two doses of psilocybin in controlled medical settings while undergoing brain imaging. The study found that psilocybin consistently produced positive, lasting improvements in mood, well-being, and spiritual outlook, regardless of whether people had used psychedelics before, their sex, or the specific imaging setting used.

Research Topic: Mental health